Novavax, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Charles Jacobs
- Full Time Employees
- 749
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 21 Firstfield Road Gaithersburg MD United States of America 20878
- IPO Date
- Dec 5, 1995
- CIK
- 0001000694
- Website
- novavax.com
- Similar Companies
- Business
- Novavax, Inc., a biotechnology enterprise, dedicates itself to the research, advancement, and market introduction of vaccines aimed at preventing significant infectious illnesses. The company's lead commercial offering, Nuvaxovid, is a protein-based COVID-19 vaccine, which has secured full regulatory approval in the U.S. for adults aged 65 and older, as well as individuals 12 to 64 years old with specific elevated risk factors, providing a non-mRNA alternative. Its pipeline relies on a proprietary recombinant nanoparticle technology and the Matrix-M adjuvant. Important investigational programs feature a COVID-19-Influenza Combination vaccine and a standalone seasonal influenza vaccine, both advancing through Phase 3 clinical trials. Furthermore, a respiratory syncytial virus (RSV) F protein nanoparticle vaccine candidate remains under development. The company actively engages in strategic alliances, including a significant collaboration with Sanofi for the co-commercialization of Nuvaxovid and joint development of combination vaccines, and a partnership with Takeda for its COVID-19 vaccine in Japan. Novavax, Inc. was founded in 1987 and is based in Gaithersburg, Maryland.
Company News
Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors
Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What Happened
Novavax shareholder Shah Capital to step back from activist role
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NASDAQ:NVAX) Stock Jumps 10.5% – Should You Buy?
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
Novavax Stock Falls Back: What's Going On?
Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna Nudges Higher, Pfizer Inches Higher
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Novavax Shorts on Edge as Russia Plague Fears Spread
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?